IMAB
Price:
$2.88
Market Cap:
$1.16B
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced programs, Eftansomatropin alfa, a long-acting human growth hormone, has successfully completed Phase 3 clinical trials for pediatric growth hormone deficiency. Similarly, Lemzoparlimab, a CD47 monoclonal antibody, has concluded its Phase 2 clinical evaluation. Other notable assets include Felzartamab, a CD38 antibody currently undergoing Phase 1b/2a develop...[Read more]
Industry
Biotechnology
IPO Date
2020-01-17
Stock Exchange
NASDAQ
Ticker
IMAB
According to I-Mab’s latest financial reports and current stock price. The company's current Enterprise Value is 1.13B. This represents a change of -146.84% compared to the average of -2415981507.13 of the last 4 quarters.
The mean historical Enterprise Value of I-Mab over the last ten years is 5.67B. The current 1.13B Enterprise Value has changed 1.90% with respect to the historical average. Over the past ten years (40 quarters), IMAB's Enterprise Value was at its highest in in the June 2021 quarter at 35.49B. The Enterprise Value was at its lowest in in the September 2025 quarter at -10213366639.67.
Average
5.67B
Median
3.56B
Minimum
-796748604.48
Maximum
22.32B
Discovering the peaks and valleys of I-Mab Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 302.81%
Maximum Annual Enterprise Value = 22.32B
Minimum Annual Increase = -204.70%
Minimum Annual Enterprise Value = -796748604.48
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 136.04M | 302.81% |
| 2024 | 33.77M | -95.95% |
| 2023 | 834.23M | -204.70% |
| 2022 | -796748604.48 | -103.57% |
| 2021 | 22.32B | 37.36% |
| 2020 | 16.25B | 300.57% |
| 2019 | 4.06B | 14.02% |
| 2018 | 3.56B | -23.25% |
The current Enterprise Value of I-Mab (IMAB) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
334.68M
5-year avg
4.51B
10-year avg
5.67B
I-Mab’s Enterprise Value is greater than Galectin Therapeutics Inc. (297.44M), greater than Design Therapeutics, Inc. (675.12M), greater than DiaMedica Therapeutics Inc. (299.78M), greater than Aura Biosciences, Inc. (343.72M), greater than Rocket Pharmaceuticals, Inc. (275.44M), greater than Annexon, Inc. (413.52M), greater than Alpha Tau Medical Ltd. (895.61M), greater than LB Pharmaceuticals Inc Common Stock (497.78M), greater than enGene Holdings Inc. (79.79M), greater than Altimmune, Inc. (168.60M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 297.44M | $175.84M | |
| 675.12M | $685.15M | |
| 299.78M | $304.44M | |
| 343.72M | $411.52M | |
| 275.44M | $300.28M | |
| 413.52M | $563.29M | |
| 895.61M | $889.71M | |
| 497.78M | $814.99M | |
| 79.79M | $82.94M | |
| 168.60M | $230.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like I-Mab using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like I-Mab or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is I-Mab's Enterprise Value?
What is the highest Enterprise Value for I-Mab (IMAB)?
What is the 3-year average Enterprise Value for I-Mab (IMAB)?
What is the 5-year average Enterprise Value for I-Mab (IMAB)?
How does the current Enterprise Value for I-Mab (IMAB) compare to its historical average?